FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, immunology and microbiology, in particular to mRNA-based vectors containing certain 5'- and 3'-non-translated regions for increased production of the target protein, as well as to a method for using the said vectors for the synthesis of the target protein in cells mammals.
EFFECT: invention provides for the creation of an mRNA-based vector that is stable and provides increased levels of target protein production, such as a vaccine antigen, antibody, therapeutic protein or enzyme.
8 cl, 7 dwg, 2 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| EXPRESSION VECTOR BASED ON ADENO-ASSOCIATED VIRUS CARRYING RECOMBINANT ANTIBODY GENES AND ITS USE FOR PREVENTION OF DISEASES CAUSED BY INFLUENZA A VIRUS AND SARS-CoV-2 VIRUS | 2023 |
|
RU2817792C1 |
| EXPRESSION VECTOR BASED ON ADENO-ASSOCIATED VIRUS AND METHOD OF ITS USE FOR EMERGENCY PREVENTION AND PROPHYLAXIS OF DISEASES CAUSED BY SARS-CoV-2 VIRUS (VERSIONS) | 2022 |
|
RU2777404C1 |
| MEANS AND METHOD FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY THE SARS-COV-2 VIRUS BASED ON A RECOMBINANT ANTIBODY AND A HUMANIZED MONOCLONAL ANTIBODY | 2021 |
|
RU2769223C1 |
| SINGLE-DOMAIN ANTIBODY AND ITS MODIFICATIONS THAT SPECIFICALLY BIND TO RBDS PROTEIN OF SARS-COV-2 VIRUS, AND METHOD FOR THEIR USE FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY SARS- COV-2 VIRUS | 2021 |
|
RU2763001C1 |
| PLASMID pVAX-RBD DNA MATRIX OF mRNA-RBD MOLECULES, OBTAINED USING THE pVAX - RBD DNA MATRIX, PROVIDING THE SYNTHESIS AND SECRETION OF THE RBD PROTEIN SARS-CoV 2 IN MAMMALIAN CELLS AND A COMPLEX IN THE FORM OF NANOPARTICLES CONTAINING mRNA-RBD MOLECULES THAT INDUCE SARS-CoV-SPECIFIC ANTIBODIES WITH VIRAL NEUTRALIZING ACTIVITY | 2021 |
|
RU2754230C1 |
| IMMUNOBIOLOGICAL AGENT AND METHOD FOR ITS USE FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST VIRUSES SARS-COV-2 VARIANT B.1.617.2 (DELTA) AND SARS-COV-2 VARIANT B.1.1.529 (OMICRON) (VARIANTS) | 2022 |
|
RU2779634C1 |
| HUMANIZED MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO RBD S OF THE PROTEIN OF THE SARS-COV-2 VIRUS, AGENT AND METHOD FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY SARS-COV-2 VIRUS | 2021 |
|
RU2765731C1 |
| RECOMBINANT PLASMID PVBL-RBDDELTA PROVIDING SYNTHESIS AND SECRETION OF THE RECOMBINANT RECEPTOR-BINDING DOMAIN (RBD) OF THE SARS-COV-2 CORONAVIRUS LINE B.1.617.2 IN MAMMALIAN CELLS | 2021 |
|
RU2772904C1 |
| RECOMBINANT PLASMID PVBL-RBDOMIK PROVIDING SYNTHESIS AND SECRETION OF THE RECOMBINANT RECEPTOR-BINDING DOMAIN (RBD) OF THE SARS-COV-2 CORONAVIRUS LINE B.1.1.529 IN MAMMALIAN CELLS. | 2021 |
|
RU2772905C1 |
| SINGLE-DOMAIN LLAMA ANTIBODY H5 AND ITS DERIVATIVE H5-Fc SPECIFICALLY BINDING THE RBD DOMAIN OF THE S-PROTEIN OF THE SARS-CoV-2 VIRUS POSSESSING VIRUS-NEUTRALIZING ACTIVITY | 2022 |
|
RU2793967C1 |
